Steward Cross
Concise Prescribing Info
Schizophrenia; acute manic & mixed episodes associated w/ bipolar disorder; adjunctive therapy to antidepressants for the treatment of major depressive disorder.
Dosage/Direction for Use
Schizophrenia Recommended starting & target dose: 10 or 15 mg/day. Usual dose range: 10-30 mg/day. Dose increase should not be made before 2 wk, the time needed to achieve steady state. Bipolar disorder Initially 30 mg once daily; decrease to 15 mg based on tolerability. Adjunctive treatment of major depressive disorder Initially 2-5 mg/day. Recommended dose range: 2-15 mg/day. Dosage adjustment of up to 5 mg/day should occur gradually at intervals of no <1 wk.
May be taken with or without food.
Special Precautions
Increased mortality in elderly patients w/ dementia-related psychosis. Increased incidence of cerebrovascular adverse events (eg, stroke, transient ischemic attack), including fatalities. May worsen depression &/or emergence of suicidal ideation & behaviour or unusual changes in behaviour in patients w/ major depressive disorder. Patient w/ depressive symptoms should be adequately screened for bipolar disorder prior to initiating treatment w/ antidepressants. Neuroleptic malignant syndrome. Consider discontinuation if signs & symptoms of tardive dyskinesia appear. Identify all possible risk factors for venous thromboembolism before & during treatment. Hyperglycemia & DM (monitor patient for worsening of glucose control). Wt gain. Patients w/ known CV disease (history of MI or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease or conditions which would predispose patients to hypotension (dehydration, hypovolemia & treatment w/ antihypertensives). Perform a complete blood count & monitor patients w/ history of clinically significant low WBC/ANC or drug-induced leukopenia/neutropenia during the 1st few mth of therapy. Discontinue in patients w/ severe neutropenia (ANC <1,000/mm3). Pathological gambling & other compulsive behaviours. History of seizures or those w/ a lowered seizure threshold. Patients who will be experiencing conditions which may contribute to an elevation in core body temp & those at risk for aspiration pneumonia. Dysphagia. Close supervision of high-risk suicidal patients. Avoid overheating & dehydration. Patients w/ sleep apnoea or risk factors for developing sleep apnoea. May affect ability to drive or operate machinery. Pregnancy & lactation. Not approved for use in treating depression in paed population. Not approved for treatment in patients w/ psychosis associated w/ Alzheimer's disease.
Adverse Reactions
Nausea, vomiting, constipation, headache, dizziness, akathisia, anxiety, insomnia & restlessness; sedation, tremor, extrapyramidal disorder.
Drug Interactions
Increased exposure w/ strong CYP3A4 inhibitors (eg, itraconazole, clarithromycin) or strong CYP2D6 inhibitors (eg, quinidine, fluoxetine, paroxetine). Decreased exposure w/ strong CYP3A4 inducers (eg, carbamazepine & rifampin). May enhance the effect of antihypertensive agents. Greater intensity of sedation in combination w/ benzodiazepines (eg, lorazepam). Avoid alcohol.
MIMS Class
ATC Classification
N05AX12 - aripiprazole ; Belongs to the class of other antipsychotics.
Abilify tab 5 mg
Abilify tab 10 mg
Abilify tab 15 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in